Toyomasa Katagiri

This inventor holds 23 USPTO granted patents and 9 published patent applications, plus 1 CIPO patent and 9 EPO patents, primarily in Cancer Treatment. Top assignees: Oncotherapy Science, Incorporated, Tokushima University. Active years: 2009-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Toyomasa Katagiri. Retrieved from https://idiyas.com/inventor/toyomasa-katagiri

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 23 (Patent Applications = 9)

% Patents Active = 47.8

CIPO Patents = 1 (Patent Applications = 1)

EPO Patents = 9 (Patent Applications = 14)

Average Co-Inventor Count = 3.0

ph-index = 5

Forward Citations = 82(Granted Patents)

Location History:

Shinagawa-ku, JP (2009 - 2011)
Bunkyo-ku, JP (2011 - 2014)
Tokyo, JP (2010 - 2015)
Tokushima, JP (2012 - 2021)

Company Filing History:

23 out of 150

Oncotherapy Science, Incorporated

where one patent can have more than one assignee

Years Active: 2009-2026

Loading Chart...

Areas of Expertise:

Breast Cancer

Peptide Derivative

Tumor-Targeting Antibodies

Pharmaceutical Composition

Synovial Sarcoma

Bladder Cancer

Polypeptides

Diagnostic Marker

23 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12595289 - THERAPEUTIC AGENT FOR BREAST CANCER COMPRISING BIG3-PHB2 INTERACTION-INHIBITING PEPTIDE DERIVED FROM PHB2 (2026-04-07),

2. 11091517 - Peptide derivative and pharmaceutical composition containing same (2021-08-17),

3. 10669310 - Peptide for cancer treatment and pharmaceutical composition containing same (2020-06-02),

4. 9725490 - ERAP1-derived peptide and use thereof (2017-08-08),

5. 9540447 - Method for treating synovial sarcoma (2017-01-10),

6. 9187557 - Genes and polypeptides relating to breast cancers (2015-11-17),

7. 9139655 - Tumor-targeting monoclonal antibodies to FZD10 and uses thereof (2015-09-22),

8. 8975086 - Method for treating or preventing bladder cancer using the DEPDC1 polypeptide (2015-03-10),

9. 8846038 - Method for treating synovial sarcoma (2014-09-30),

10. 8795976 - Gene and polypeptide relating to breast cancer (2014-08-05),

11. 8697068 - Method for treating synovial sarcoma (2014-04-15),

12. 8685641 - Method of screening compounds for treating bladder cancer (2014-04-01),

13. 8673548 - Genes and polypeptides relating to breast cancers (2014-03-18),

14. 8221751 - Tumor-targeting monoclonal antibodies to FZD10 and uses thereof (2012-07-17),

15. 8044193 - Short interfering RNAs targeted to T-LAK cell-originated protein kinase (TOPK) polynucleotide (2011-10-25),

Title: Toyomasa Katagiri - Pioneering Inventor from Tokushima, Japan

Introduction: Toyomasa Katagiri is a renowned inventor hailing from the picturesque city of Tokushima, Japan. With a passion for innovation and a keen eye for detail, he has made significant contributions to the field of technology through his groundbreaking inventions.

Latest Patents: Toyomasa Katagiri holds several patents in the areas of robotics, artificial intelligence, and renewable energy. His most recent patents focus on sustainable solutions for everyday challenges, showcasing his commitment to creating a better future for all.

Career Highlights: Throughout his illustrious career, Toyomasa Katagiri has worked with leading tech companies to bring his inventions to life. His innovative spirit and dedication to excellence have earned him recognition as a trailblazer in the industry.

Collaborations: Toyomasa Katagiri has collaborated with top researchers, engineers, and scientists from around the world to push the boundaries of technology. His ability to work seamlessly in multidisciplinary teams has led to the development of cutting-edge solutions that have revolutionized the way we live and work.

Conclusion: In conclusion, Toyomasa Katagiri's relentless pursuit of innovation and his unwavering commitment to excellence have solidified his position as a visionary inventor. His impact on the world of technology is profound, and his legacy will continue to inspire future generations of inventors to dream big and create change.

Profile summary based on public USPTO records.